章程 2025 年 10 月 | 第一章 | 总 则 2 | | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股 份 4 | | | 第一节 | 股份发行 | 4 | | 第二节 | 股份增减和回购 | 5 | | 第三节 | 股份转让 | 6 | | 第四章 | 股东和股东会 | 7 | | 第一节 | 股东的一般规定 | 7 | | 第二节 | 控股股东和实际控制人 9 | | | 第三节 | 股东会的一般规定 | 10 | | 第四节 | 股东会的召集 | 13 | | 第五节 | 股东会的提案与通知 | 15 | | 第六节 | 股东会的召开 | 16 | | 第七节 | 股东会的表决和决议 | 19 | | 第五章 | 董事和董事会 | 23 | | 第一节 | 董事的一般规定 | 23 | | 第二节 | 董事会 | 26 | | 第三节 | 独立董事 30 | | | 第四节 | 董事会专门委员会 | 33 | | 第六章 | 总经理（总裁）及其他高级管理人员 | 34 | | 第七章 | 财务会计制度、利润分配和审计 | 36 | | 第 ...

Core Insights - Samsung Medical reported a third-quarter revenue of 3.108 billion, a year-on-year decrease of 9.56% [1] - The net profit for the third quarter was 298 million, reflecting a year-on-year decline of 55.22% [1] - For the first three quarters, the total revenue reached 11.08 billion, showing a year-on-year growth of 6.19% [1] - The net profit for the first three quarters was 1.528 billion, which represents a year-on-year decrease of 15.85% [1]

Investment Rating - The report maintains a "Buy" rating for multiple companies in the energy and power equipment sector, including Ningde Times, Pinggao Electric, Guoneng Rixin, Sany Renewable Energy, and others [4][7][8]. Core Insights - The report emphasizes the importance of a comprehensive green transition in China's economy, driven by goals of carbon peak and carbon neutrality, with a focus on developing a new energy system [1][2]. - The dual control of carbon emissions is expected to expand the demand for green electricity, with policies promoting both carbon market management and mandatory green electricity consumption [2][3]. - The energy sector's green and low-carbon transformation is identified as a critical area for achieving overall green transition goals, with a significant portion of new electricity demand expected to be met by clean energy sources by the end of the 14th Five-Year Plan [3]. Summary by Sections Section 1: Industry Overview - The report highlights the acceleration of green transformation in the economy, with key measures including the establishment of a dual control system for carbon emissions and the promotion of green energy transition [1][2]. Section 2: Company Recommendations - **Ningde Times (300750 CH)**: Target price raised to 566.18 CNY, with a strong outlook on electric vehicle and energy storage markets [9][10]. - **Pinggao Electric (600312 CH)**: Target price set at 22.80 CNY, benefiting from strong domestic bidding for power transmission and transformation equipment [11]. - **Guoneng Rixin (301162 CH)**: Target price of 73.54 CNY, with significant growth in service stations and customer retention [12]. - **Sany Renewable Energy (688349 CH)**: Target price increased to 38.01 CNY, with expectations of improved profitability in wind turbine sales [14]. - **Siyuan Electric (002028 CH)**: Target price raised to 147.90 CNY, driven by strong growth in overseas orders and data center demand [14]. - **Sungrow Power Supply (300274 CH)**: Target price set at 195.40 CNY, with a focus on energy storage and international expansion [14]. - **Oriental Electronics (000682 CH)**: Target price of 13.86 CNY, with steady growth in core business and new energy projects [14]. - **China Western Power (601179 CH)**: Target price set at 8.25 CNY, with a stable growth outlook in power transmission equipment [14]. - **Guodian NARI Technology (600406 CH)**: Target price of 26.00 CNY, benefiting from new power system construction [14].

证券代码：601567 证券简称：三星医疗 公告编号：临2025-081 宁波三星医疗电气股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 975,350.00 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 80.73% | | 100% 特别风险提示（如有请勾选） | □对外担保总额超过最近一期经审计净资产 | | | 担保金额超过上市公司最近一期经审计净 | | 资产 | 50% | | | □对合并报表外单位担保金额达到或超过最 | | | 近一期经审计净资产 30%的情况下 | | | 对资产负债率超过 70%的单位提供担保 | | 其他风险提示（如有） 无 | | 注：表中截至本公告日上市公司及其控股子公司对外担保总额，包含年度已批准的担 保额度内尚未使用额度与担保实际发生余额之和，并非公司实际发生的担保余 ...

华鑫证券研报指出，三星医疗上半年公司海外实现营业收入14.95亿元，同比增长51%。其中，海外配 电重点突破欧洲、中东、拉美优势市场，继前期在沙特、墨西哥、希腊、巴西取得首单后，2025年上半 年又在匈牙利、罗马尼亚、吉尔吉斯斯坦取得首单突破；海外用电深耕高端、发力新兴，加强布局北 美、非洲潜力市场。同时，公司持续深耕本地化经营，新增欧洲匈牙利销售公司，为海外配电业务拓展 提供有力支撑。公司在手订单总计176.32亿元，同比增长18.39%。其中海外配电在手订单21.82亿元， 同比增长123.96%。考虑到公司海外订单高增长，国内网内领先，网外突破，给予"买入"投资评级。 ...

Core Viewpoint - Samsung Medical achieved significant growth in overseas revenue, indicating strong market expansion and order growth, particularly in Europe and emerging markets [1] Group 1: Overseas Revenue Growth - The company reported overseas revenue of 1.495 billion yuan in the first half of the year, representing a year-on-year increase of 51% [1] - Key breakthroughs in overseas distribution were made in Europe, the Middle East, and Latin America, with initial orders secured in Hungary, Romania, and Kyrgyzstan in the first half of 2025 [1] Group 2: Order Backlog - The total order backlog for the company reached 17.632 billion yuan, reflecting a year-on-year growth of 18.39% [1] - The overseas distribution order backlog amounted to 2.182 billion yuan, showing a substantial year-on-year increase of 123.96% [1] Group 3: Strategic Initiatives - The company is focusing on high-end markets and emerging regions, enhancing its presence in North America and Africa [1] - A new sales company was established in Hungary to support the expansion of overseas distribution business [1]

Core Viewpoint - The report by Zhiyan Consulting highlights a significant decline in the production of electrical instruments and meters in China, with a projected decrease in output for 2025 compared to previous years [1]. Industry Summary - According to data from the National Bureau of Statistics, the production of electrical instruments and meters in China for August 2025 is expected to be 21.77 million units, representing a year-on-year decrease of 12.2% [1]. - From January to August 2025, the cumulative production of electrical instruments and meters in China is reported to be 178.886 million units, showing a cumulative decline of 8.2% [1]. - The report provides a comprehensive analysis of the supply and demand forecast for the Chinese instrument and meter market from 2025 to 2031, indicating potential challenges in the industry [1]. Company Summary - Listed companies mentioned in the report include Weisheng Information (688100), Linyang Energy (601222), Samsung Medical (601567), Haixing Electric (603556), XJ Electric (000400), Pinggao Electric (600312), Guodian Nanzi (600268), *ST Huayi (600290), Dongfang Electronics (000682), and Kelon Electronics (002121) [1].

Investment Rating - The report assigns a "Buy" rating for the company, Samsung Medical (601567.SH) [1][8] Core Insights - The company has experienced significant growth in overseas orders, with a 51% year-on-year increase in overseas revenue, reaching 1.495 billion yuan [4] - The company is expanding its production capacity to alleviate bottlenecks in its distribution business, with a new project expected to produce 16,000 sets of new energy box substations annually [4] - The company maintains a leading position in domestic power grid business and has made breakthroughs in non-grid business sectors, particularly in renewable energy [5][7] Summary by Sections Market Performance - The stock price is currently at 24 yuan, with a market capitalization of 33.7 billion yuan and a 52-week price range of 21.21 to 34.48 yuan [1] Financial Performance - In the first half of the year, the company achieved operating revenue of 7.97 billion yuan, a 14% increase year-on-year, and a net profit of 1.23 billion yuan, up 7% [3] - The gross margin for the first half was 28.97%, down 5.64 percentage points year-on-year, while the net margin was 15.43%, down 1 percentage point [3] Order Backlog and Growth - The total order backlog reached 17.632 billion yuan, an 18.39% increase year-on-year, with overseas distribution orders growing by 123.96% to 2.182 billion yuan [4] - The company is focusing on high-end markets in Europe, the Middle East, and Latin America, with successful bids in Hungary, Romania, and Kyrgyzstan [4] Profit Forecast - Revenue projections for 2025-2027 are 16.1 billion, 18.9 billion, and 22.4 billion yuan, respectively, with corresponding EPS of 1.76, 2.14, and 2.62 yuan [8][10]

截至2025年10月17日收盘，三星医疗（601567）报收于24.0元，较上周的26.5元下跌9.43%。本周，三 星医疗10月14日盘中最高价报26.7元。10月17日盘中最低价报23.86元。三星医疗当前最新总市值337.25 亿元，在电网设备板块市值排名8/123，在两市A股市值排名534/5158。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 本周关注点 公司公告汇总：三星医疗2025年半年度每股派发现金红利0.485元（含税），股权登记日为2025年 10月17日。 公司公告汇总：本次权益分派以扣除回购股份后的1,399,454,029股为基数，每10股派4.85元，不送 红股，不转增股本。 公司公告汇总：差异化分红对除权除息参考价影响约为0.0090%，影响较小，符合相关法规及章 程规定。 公司公告汇总 三星医疗2025年半年度权益分派实施公告：每股现金红利0.485元（含税），股权登记日为2025年10月 17日，除权（息）日及现金红利发放日为2025年10月20日。利润分配以总股本1,405,209,400股扣 ...

Group 1 - On October 15, Samsung Medical's stock rose by 2.07%, with a trading volume of 555 million yuan [1] - The financing data shows that on the same day, Samsung Medical had a financing purchase amount of 54.05 million yuan and a net financing purchase of 9.43 million yuan [1] - As of October 15, the total balance of margin trading for Samsung Medical was 375 million yuan, with a financing balance of 372 million yuan, accounting for 1.01% of the circulating market value [1] Group 2 - As of June 30, the number of shareholders of Samsung Medical increased to 29,000, a rise of 76.91%, while the average circulating shares per person decreased by 43.15% to 48,732 shares [2] - For the first half of 2025, Samsung Medical achieved an operating income of 7.972 billion yuan, a year-on-year increase of 13.93%, and a net profit attributable to the parent company of 1.230 billion yuan, up 6.93% year-on-year [2] Group 3 - Samsung Medical has distributed a total of 6.407 billion yuan in dividends since its A-share listing, with 3.329 billion yuan distributed in the last three years [3] - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder of Samsung Medical, holding 47.9803 million shares, an increase of 3.9134 million shares compared to the previous period [3]